Robert Kieszko

629 total citations
35 papers, 237 citations indexed

About

Robert Kieszko is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Robert Kieszko has authored 35 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 10 papers in Epidemiology. Recurrent topics in Robert Kieszko's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers), Sarcoidosis and Beryllium Toxicity Research (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert Kieszko is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers), Sarcoidosis and Beryllium Toxicity Research (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert Kieszko collaborates with scholars based in Poland and Sweden. Robert Kieszko's co-authors include Janusz Milanowski, Paweł Krawczyk, Sylwia Chocholska, Izabela Chmielewska, Michał Szczyrek, Anna Grenda, Bożena Jarosz, Tomasz Kucharczyk, Arkadiusz Bomba and Anna Dmoszyńska and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Robert Kieszko

32 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Kieszko Poland 10 106 85 81 61 25 35 237
Takeshi Masubuchi Japan 8 172 1.6× 54 0.6× 96 1.2× 36 0.6× 79 3.2× 16 339
Sara Teolato Italy 2 127 1.2× 38 0.4× 160 2.0× 43 0.7× 38 1.5× 3 212
Axel Klenk Switzerland 6 125 1.2× 63 0.7× 66 0.8× 15 0.2× 34 1.4× 6 288
Assaf Stein Israel 10 72 0.7× 109 1.3× 38 0.5× 110 1.8× 12 0.5× 22 325
Rui‐Hong Du United States 12 206 1.9× 100 1.2× 93 1.1× 21 0.3× 76 3.0× 14 350
Baiqiang Lin China 9 57 0.5× 207 2.4× 65 0.8× 78 1.3× 13 0.5× 12 338
Roberto Cruz-Gervis United States 5 221 2.1× 34 0.4× 58 0.7× 50 0.8× 36 1.4× 6 314
Sean Mateer Australia 7 86 0.8× 156 1.8× 54 0.7× 35 0.6× 112 4.5× 9 365
Soichiro Ueda Japan 9 102 1.0× 42 0.5× 107 1.3× 14 0.2× 51 2.0× 25 273
Tai-Jong Chao Taiwan 5 50 0.5× 35 0.4× 32 0.4× 31 0.5× 24 1.0× 8 232

Countries citing papers authored by Robert Kieszko

Since Specialization
Citations

This map shows the geographic impact of Robert Kieszko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Kieszko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Kieszko more than expected).

Fields of papers citing papers by Robert Kieszko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Kieszko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Kieszko. The network helps show where Robert Kieszko may publish in the future.

Co-authorship network of co-authors of Robert Kieszko

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Kieszko. A scholar is included among the top collaborators of Robert Kieszko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Kieszko. Robert Kieszko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grenda, Anna, Barbara Kuźnar-Kamińska, Arkadiusz Bomba, et al.. (2025). Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients. Scientific Reports. 15(1). 6139–6139. 6 indexed citations
2.
Grenda, Anna, Arkadiusz Bomba, Dariusz Wasyl, et al.. (2024). Gut resistome of NSCLC patients treated with immunotherapy. Frontiers in Genetics. 15. 1378900–1378900. 2 indexed citations
3.
Chmielewska, Izabela, et al.. (2024). Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review. Translational Lung Cancer Research. 13(10). 2491–2499. 1 indexed citations
4.
Grenda, Anna, et al.. (2023). Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes—A Case Report with Literature Review. International Journal of Molecular Sciences. 24(2). 1195–1195. 2 indexed citations
5.
Krawczyk, Paweł, et al.. (2022). The efficacy of T790M mutation testing in liquid biopsy—Real clinic data. PLoS ONE. 17(5). e0267846–e0267846. 2 indexed citations
6.
Grenda, Anna, Izabela Chmielewska, Paweł Krawczyk, et al.. (2022). Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer. AMB Express. 12(1). 86–86. 42 indexed citations
7.
Krawczyk, Paweł, Kamila Wojas‐Krawczyk, Anna Grenda, et al.. (2022). Different MET gene alterations in lung adenocarcinoma patients. Oncology in Clinical Practice.
8.
9.
Krawczyk, Paweł, Anna Grenda, Kamila Wojas‐Krawczyk, et al.. (2021). Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. Scientific Reports. 11(1). 20939–20939. 6 indexed citations
10.
Kowalski, Dariusz M., Grzegorz Czyżewicz, Maciej Bryl, et al.. (2020). Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland. Advances in respiratory medicine. 88(3). 189–196. 1 indexed citations
11.
Nicoś, Marcin, Kamila Wojas‐Krawczyk, Paweł Krawczyk, et al.. (2019). Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. Archives of Medical Science. 16(6). 1496–1500. 1 indexed citations
12.
Krawczyk, Paweł, et al.. (2019). The effectiveness of chemotherapy in small cell lung cancer patients with BRCA2 gene mutation and Schwartz-Bartter syndrome. Oncology in Clinical Practice. 15(2). 120–123. 1 indexed citations
13.
Kieszko, Robert, Paweł Krawczyk, Tomasz Powrózek, et al.. (2015). The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings. Archives of Medical Science. 6(6). 1263–1272. 6 indexed citations
14.
Pietrzak, Aldona, et al.. (2015). Ultrasound findings in cutaneous sarcoidosis: report of a case. Advances in Dermatology and Allergology. 1(1). 51–55. 9 indexed citations
15.
Kieszko, Robert, et al.. (2013). Good’s syndrome twelve years after thymectomy due to thymoma. A case study. Central European Journal of Immunology. 38(4). 505–510. 1 indexed citations
16.
Krawczyk, Paweł, Dariusz M. Kowalski, Michał Szczyrek, et al.. (2013). Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. Oncology Reports. 30(3). 1463–1472. 6 indexed citations
17.
Kieszko, Robert, Paweł Krawczyk, Sylwia Chocholska, et al.. (2006). Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respiratory Medicine. 101(3). 645–654. 16 indexed citations
18.
Kieszko, Robert, et al.. (2006). The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respiratory Medicine. 101(4). 722–728. 25 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeshi Masubuchi Breakdown of academic impact, for papers by Sara Teolato Breakdown of academic impact, for papers by Axel Klenk Breakdown of academic impact, for papers by Assaf Stein Breakdown of academic impact, for papers by Rui‐Hong Du Breakdown of academic impact, for papers by Baiqiang Lin Breakdown of academic impact, for papers by Roberto Cruz-Gervis Breakdown of academic impact, for papers by Sean Mateer Breakdown of academic impact, for papers by Soichiro Ueda Breakdown of academic impact, for papers by Tai-Jong Chao
Rankless by CCL
2026